Skip to content

US FDA approves second Indian generic HIV drug for use by PEPFAR

Traditional risk factors, not PIs or HIV cause hardening of arteries in US study

TMC114 expanded access programme announced: regulatory approval to be sought early next year

Tenofovir may linger up to 3 weeks in body: discontinue with caution

Meta-analysis highlights wide variation in success of developing world HIV treatment

Traditional healers being integrated into HIV care and treatment in Kwazulu-Natal

Response to HAART improves due to better drugs and more expertise in their use

Rifampicin resistance linked to dosing schedule in HIV-positive TB patients

PEPFAR working closely with South African government to support HIV treatment and care